SPP1 + TAMs and C1QC + TAMs, associated with tumor angiogenesis and phagocytosis respectively, highlight the potential of targeting distinct TAM subpopulations to influence immunotherapy effectiveness [62]. This evidence concerns the gene SPP1 and neoplasm.